4 completed, 1 unknown. 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 2, Unknown 1 |
Follow Nalagenetics Pte Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Perspective of Healthy Individuals on Breast Cancer Risk Prediction Report In The Indonesian Population Focus Group Discussion - Breast Cancer | Not applicable | Completed | Nalagenetics Pte Ltd | 10 | 2022-11-08 | 2023-11-13 |
| Implementation of Pre-emptive Pharmacogenomics Testing in Singapore-based Private Hospital Institutions (IMPT Study) Pharmacogenomics Testing - Pre-emptive Pharmacogenomics | Completed | Nalagenetics Pte Ltd | 222 | 2022-10-03 | 2025-05-30 | |
| CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population Tamoxifen - Breast Cancer | Not applicable | Unknown | Nalagenetics Pte Ltd | 150 | 2021-01-01 | 2022-08-19 |
| Genetic and Non-Genetic Breast Cancer Risk Prediction Evaluation in Indonesian Samples Breast Cancer Risk Prediction Software - Breast Cancer | Completed | Nalagenetics Pte Ltd | 322 | 2020-10-13 | 2023-09-13 | |
| Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels Tamoxifen dose adjustment - ER+ Breast Cancer | Not applicable | Completed | Nalagenetics Pte Ltd | 151 | 2019-09-06 | 2021-08-05 |
Breast Neoplasms (4) · Genetic Risk Score (1)
Tamoxifen (1)
Indonesia (4) · Singapore (1)
Samuel Haryono, MD, PhD (2) · Arief Winata, MD (1) · Baitha Maggadani, MPharm (1) · Baitha P. Maggadani (1) · Eric A Fernandez, Ph.D. (1) · Fatma Aldila, MPH (1) · Fatma Aldila, PharmD (1) · Faustina A Agatha, S. Biotek (1) · Melvin Wong, Dr (1) · Sabrina G Tanu, B. Sci (1) · Samuel J Haryono, Ph.D., MD (1)